Effects of aripiprazole long-acting two-injection start in patients diagnosed with schizophrenia in Huelva (Spain)
Introduction Improving outcomes in schizophrenia generally involves an improvement in drug adherence. Aripiprazole two-injection start (TIS) is the newest option of available on the market, with limited data on its effects. Objectives It was our goal to evaluate whether TIS has an effect on hospita...
Main Authors: | A. Moleon, L. Duque, M. Martin-Bejarano |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2023-03-01
|
Series: | European Psychiatry |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933823022150/type/journal_article |
Similar Items
-
Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen
by: S.L. Romero Guillena, et al.
Published: (2022-06-01) -
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
by: Saki Hattori, et al.
Published: (2023-03-01) -
Aripiprazole lai two-injection start in a 16 year-old with Schizophrenia
by: B. Marpepa, et al.
Published: (2022-06-01) -
Aripiprazole LAI two‐injection start in a 16 year‐old adolescent with schizophrenia
by: Virginio Salvi, et al.
Published: (2022-06-01) -
The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
by: Christopher Evernden, BSc, BScPharm, ACPR, et al.
Published: (2021-09-01)